Tumour gene expression signature in primary melanoma predicts long-term outcomes
Open accessPublished version of a preprint
The DOI matches its Crossref record; 66 of the 69 references it cites were found in a registry or an index.
Abstract
Adjuvant systemic therapies are now routinely used following resection of stage III melanoma, however accurate prognostic information is needed to better stratify patients. We use differential expression analyses of primary tumours from 204 RNA-sequenced melanomas within a large adjuvant trial, identifying a 121 metastasis-associated gene signature. This signature strongly associated with progression-free (HR = 1.63, p = 5.24 × 10 −5 ) and overall survival (HR = 1.61, p = 1.67 × 10 −4 ), was validated in 175 regional lymph nodes metastasis as well as two externally ascertained datasets. The machine learning classification models trained using the signature genes performed significantly better in predicting metastases than models trained with clinical covariates ( p AUROC = 7.03 × 10 −4 ), or published prognostic signatures ( p AUROC < 0.05). The signature score negatively correlated with measures of immune cell infiltration (ρ = −0.75, p < 2.2 × 10 −16 ), with a higher score representing reduced lymphocyte infiltration and a higher 5-year risk of death in stage II melanoma. Our expression signature identifies melanoma patients at higher risk of metastases and warrants further evaluation in adjuvant clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“studies in other tumour types have demonstrated that T cell expansion is greater when ICIs are administered before complete surgical removal of the tumour as opposed to after surgery104.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [104]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Breiman, L. (2001) · Machine Learning · doi:10.1023/a:1010933404324 · Cited by 133,538
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Wickham, H. (2016) · Use R! · doi:10.1007/978-3-319-24277-4 · Cited by 33,115
(2014) · Climate Change 2013 – The Physical Science Basis · doi:10.1017/cbo9781107415324.004 · Cited by 23,880
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
HTSeq—a Python framework to work with high-throughput sequencing data
Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464
Regularization and Variable Selection Via the Elastic Net
Zou, H., & Hastie, T. (2005) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2005.00503.x · Cited by 20,957
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
Regularization Paths for Generalized Linear Models via Coordinate Descent
Friedman, J., Hastie, T., & Tibshirani, R. (2010) · Journal of Statistical Software · doi:10.18637/jss.v033.i01 · Cited by 19,927
Cited by
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391
“In HCC, the initial results of a phase I/II trial of the DNA-based therapeutic cancer vaccine GNOS-PV02 in combination with pembrolizumab demonstrated an ORR >30%, higher than the ORR of 14–17% observed in pivotal trials of anti-PD-1 antibodies in this context; larger confirmatory studies are…”
Toward Explainable Artificial Intelligence for Precision Pathology
Klauschen, F., Dippel, J., Keyl, P., Jurmeister, P., Bockmayr, M., Mock, A., Buchstab, O., Alber, M., Ruff, L., Montavon, G., et al. (2024) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-051222-113147 · Cited by 139
Cooperation between melanoma cell states promotes metastasis through heterotypic cluster formation
Campbell, N. R., Rao, A., Hunter, M. V., Sznurkowska, M. K., Briker, L., Zhang, M., Baron, M., Heilmann, S., Deforet, M., Kenny, C., et al. (2021) · Developmental Cell · doi:10.1016/j.devcel.2021.08.018 · Cited by 89
Self-citationPrognostic biomarkers of cutaneous melanoma
Ding, L., Gosh, A., Lee, D. J., Emri, G., Huss, W. J., Bogner, P. N., & Paragh, G. (2022) · Photodermatology Photoimmunology & Photomedicine · doi:10.1111/phpp.12770 · Cited by 53
Adjuvant therapy for stage II melanoma: the need for further studies
Lee, R. J., Mandalà, M., Long, G. V., Eggermont, A. M. M., van Akkooi, A. C. J., Sandhu, S. K., Garbe, C., & Lorigan, P. C. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.05.003 · Cited by 33
“A number of tissue-based gene expression scores have been developed including MelaGenix, Skyline, Decision-Dx melanoma, and CAM-121 CAM-121 [ 46– 50].”
Self-citation
Metadata
- Authors
- Garg, M., Couturier, D.-L., Nsengimana, J., Fonseca, N. A., Wongchenko, M., Yan, Y., Lauss, M., Jönsson, G. B., Newton-Bishop, J., Parkinson, C., Middleton, M. R., Bishop, D. T., McDonald, S., Stefanos, N., Tadross, J., Vergara, I. A., Lo, S., Newell, F., Wilmott, J. S., Thompson, J. F., Long, G. V., Scolyer, R. A., Corrie, P., Adams, D. J., Brazma, A., & Rabbie, R.
- Affiliations
- European Bioinformatics Institute (GB)
- University of Cambridge (GB)
- University of Leeds (GB)
- Universidade do Porto (PT)
- Genentech (US)
- Lund University (SE)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- University of Oxford (GB)
- The University of Sydney (AU)
- QIMR Berghofer Medical Research Institute (AU)
- Wellcome Sanger Institute (GB)
- Corresponding author
- Rabbie, Roy
- ORCID
- Garg, Manik
- Couturier, Dominique-Laurent
- Nsengimana, Jérémie
- Fonseca, Nuno A.
- Wongchenko, Matthew
- Parkinson, Christine
- Middleton, Mark R.
- Bishop, D. Timothy
- McDonald, Sarah
- Tadross, John
- Vergara, Ismael A.
- Lo, Serigne
- Newell, Felicity
- Wilmott, James S.
- Thompson, John F.
- Long, Georgina V.
- Scolyer, Richard A.
- Corrie, Pippa
- Adams, David J.
- Brazma, Alvis
- Rabbie, Roy
- Venue
- Nature Communications
- Published
- 2021-02-18
- Volume
- 12
- Issue
- 1
- Pages
- 1137-1137
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC7893180
- OpenAlex
- W3123792751
- Cited by
- 70
- References
- 69
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 15 · 2023: 11 · 2022: 20 · 2021: 7
- FWCI
- 4.83
- Type
- journal article
- Language
- en
- Update notices
- correction (2022-05-17)
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Lund University Publications (Lund University) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Apollo (cc-by)
- Apollo
- Funders
- University of Sydney Medical Foundation
- Department of Health | National Health and Medical Research Council
- Topics
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Keywords
- primary melanoma, gene expression signatures, metastasis prediction, prognostic factors, stage III melanoma, adjuvant therapy, lymph node metastasis, immune cell infiltration, overall survival, progression-free survival, stage II melanoma, machine learning classification
- MeSH terms
- Machine Learning, Progression-Free Survival, Humans, Melanoma, Neoplasm Staging, Prognosis, Time Factors, Reproducibility of Results, Gene Expression Regulation, Neoplastic, Multivariate Analysis, Proportional Hazards Models, Treatment Outcome, Gene Expression Profiling, Databases, Genetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumour gene expression signature in primary melanoma predicts long-term outcomes. https://app.cochat.ai/papers/10.1038/s41467-021-21207-2
- The paper
- Garg, M., Couturier, D.-L., Nsengimana, J., Fonseca, N. A., Wongchenko, M., Yan, Y., Lauss, M., Jönsson, G. B., Newton-Bishop, J., Parkinson, C., Middleton, M. R., Bishop, D. T., McDonald, S., Stefanos, N., Tadross, J., Vergara, I. A., Lo, S., Newell, F., Wilmott, J. S., . . . Rabbie, R. (2021). Tumour gene expression signature in primary melanoma predicts long-term outcomes. Nature Communications. https://doi.org/10.1038/s41467-021-21207-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.